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Background. Controversy exists regarding anticoagulation management following acute 2 
cardioversion in patients with early-onset (< 48 hours) atrial fibrillation without class I guideline 3 
indication for long-term oral anticoagulation (CHA2DS2-VASc 0-1). 4 
Methods and Results. A random-effect meta-analysis of observational studies reporting 30-day 5 
incidence of thromboembolic complications after cardioversion without post-procedural oral 6 
anticoagulation therapy in patients at low-moderate thromboembolic risk (CHA2DS2-VASc 0-1) 7 
was performed. Four studies were included, encompassing 3276 cardioversions. The analysis 8 
revealed that the pooled risk of 30-day incidence of thromboembolic complications in this subset of 9 
patients is low (0.10%, 95% confidence interval: 0.00-0.30%). 10 
Conclusions. Given these data, considering the bleeding risk unavoidably conferred by OAT, 11 
which is known to be higher in the first month from treatment onset, short-term anticoagulation 12 
limited to 4 weeks post-cardioversion of early-onset (< 48 hours) atrial fibrillation in patients with 13 
low-moderate risk of stroke (CHA2DS2-VASc 0-1) should be discouraged. 14 
 15 
Keywords 16 




Atrial fibrillation (AFib) cardioversion (CV) carries an inherent short-term increase in the risk of 2 
clinical thromboembolism, both in acute and in elective settings 1, 2. In case of acute cardioversion 3 
of early-onset (< 48 hours) AFib, oral anticoagulation therapy (OAT) apparently overrides this 4 
extra-risk, reducing it to the baseline thromboembolic risk of AFib patients3. However, being 5 
unanimously accepted that AFib patients not assuming OAT and presenting with high 6 
thromboembolic risk (CHA2DS2-VASc score ≥ 2) should start anticoagulation as soon as possible 7 
before CV and continue it long-term 4, 5, uncertainty regarding the best management in case of non-8 
anticoagulated individuals with low-moderate thromboembolic risk (CHA2DS2-VASc score 0-1) 9 
exists. In fact, European guidelines 4 advocate peri-procedural anticoagulation followed by short-10 
term OAT (4 weeks) also in patients without stroke risk factors (CHA2DS2-VASc 0), while the 11 
American guidelines 5 propose a less aggressive approach, suggesting that patients without 12 
additional risk factors other than female sex (CHA2DS2-VASc 0 in male, CHA2DS2-VASc 1 in 13 
female) do not necessarily need 4-week OAT post-CV. Due to this inconsistency, the aim of the 14 
present study was to perform a meta-analysis of observational studies reporting the 30-day rate of 15 
thromboembolic complications after acute cardioversion of early-onset AFib in patients at low-16 




The present meta-analysis was performed in accordance to PRISMA guidelines 6. 2 
PubMed/MEDLINE and Embase databases were searched for from their inceptions to 31st January 3 
2020, using the following string: “anticoagulation AND (acute OR early OR recent) AND 4 
cardioversion AND atrial fibrillation”. Two investigators (AS, MA) independently reviewed the 5 
titles/abstracts and studies to determine their eligibility based on the inclusion criteria and extracted 6 
all relevant outcomes of interest. Studies were eligible for inclusion if they reported the 30-day 7 
incidence of thromboembolic complications after acute CV (both pharmacological or electrical) of 8 
early-onset (< 48 hours) AFib in patients at low-moderate thromboembolic risk (CHA2DS2-VASc 9 
0-1) not assuming OAT in the 4 weeks following CV. Each CV performed during study-specific 10 
enrolling period was considered as an index observation, thus the number of CV may outweigh the 11 
number of patients included (each patient may have performed more than one CV during the 12 
investigated period). 13 
Random-effect meta-analysis (inverse variance weighting) of 30-day incidence of thromboembolic 14 
complications (please refer to Supplementary Table 1 for study-specific definition) was performed 15 
using Freeman-Tukey double arcsine transformation and the results with the corresponding 95% 16 
confidence interval (CI) were reported after back-transformation. Cochran I2 test was used to 17 
investigate heterogeneity. To deal with possible bias induced by the low number of studies included 18 
and preponderance of a single study, sensitivity analyses using inverse variance meta-analysis with 19 
different proportion transformation (logit transformation, arcsine transformation), as well as a 20 
generalized linear mixed model (GLMM) meta-analysis, were also performed. 21 
P values < 0.05 were considered statistically significant. Statistical analyses were performed with R 22 
version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria), using the package meta 7.23 
 5 
Results  1 
Initial search yielded 276 results. According to the inclusion criteria, 4 studies reporting 30-day 2 
incidence of thromboembolic complications in a cohort of AFib patients with CHA2DS2-VASc 0-1 3 
who underwent CV without anticoagulation in the 4 weeks following the procedure were finally 4 
included in the present meta-analysis 3, 8-10 (Figure 1). Table 1 summarizes main study 5 
characteristics. Meta-analytic population mainly included young men (male sex percentage range: 6 
55-65%; age range: 55-65 years), most often undergoing electrical CV (range 39-100%). In two of 7 
the included studies 3, 8, no periprocedural anticoagulation was adopted, differently from the other 8 
two studies 9, 10, where sole periprocedural anticoagulation with low molecular weight heparin 9 
(LMWH) was established in 100% and 62% of the patients, respectively.  10 
Meta-analysis of 30-day incidence of thromboembolic complications revealed a pooled estimate of 11 
0.10% (95% CI, 0.00-0.30%, I2: 0%), without significant heterogeneity. Funnel plot is reported in 12 
Figure 2. Sensitivity analyses using different meta-analytic approaches consistently produced 13 




Current guidelines are contradictory in the recommendations regarding oral anticoagulation in 2 
patients at low-moderate risk of stroke (CHA2DS2-VASc 0-1) undergoing acute CV for early-onset 3 
(< 48 hours) AFib 4, 5. In particular, the role of short-term OAT (4 weeks post-CV) in patients 4 
without indication of long-term OAT is controversial.  5 
The present analysis indicates that 30-day risk of thromboembolic complications after CV in this 6 
subset of patients (CHA2DS2-VASc 0-1, no short-term OAT) is as low as 0.1% (95% CI 0.0%-7 
0.3%). In addition, it is known that also just one month of OAT exposes the patient to an increased 8 
risk of major bleedings.  9 
Unfortunately, no specific data on 30-day major bleeding risk in this population exist, precluding 10 
direct risk-to-benefit assessment of short-term anticoagulation. However, an indirect comparison 11 
with other randomized or observational studies provides interesting insights. For example, three 12 
randomized clinical trials have recently compared direct oral anticoagulants (rivaroxaban11, 13 
edoxaban12, apixaban13) to heparin/vitamin K antagonist (VKA) in the setting of scheduled AFib 14 
cardioversion, reporting major bleeding, following cardioversion, in the range of 0.3%-0.8%. In 15 
particular, the EMANATE trial13, which compared apixaban to heparin/warfarin in AFib patients 16 
with less than 48 h anticoagulation prior to randomization, describes a clinical setting and 17 
population somewhat similar to the one investigated in this meta-analysis. Despite a slightly higher 18 
thromboembolic risk (mean CHA2DS2-VASc 2.2), 62% of the enrolled patients were naïve to OAT, 19 
and had a mean age of 64 years. In this trial, major bleeding following cardioversion occurred in 20 
0.4% of patients treated with apixaban and 0.8% of those on heparin/VKA. In addition, recent real-21 
world data from a Danish national registry 14 encompassing 54,321 patients with non-valvular AFib 22 
who initiated OAT treatment (mean CHA2DS2-VASc 2.9; mean HAS-BLED 2.2) showed that 23 
major bleeding incidence in the first 30 days of treatment was 0.82% (448 events/54,321 patients), 24 
with nearly one fifth being intracranial bleeding (17%). If we compare the 30-day (0.82%) with the 25 
 7 
1-year incidence (4.4%) of major bleedings in the latter  real-world study, it is evident that the first 1 
30 days after OAT initiation are the most vulnerable period in terms of major bleedings, thus the 4 2 
week short-term anticoagulation following cardioversion in OAC-naïve patients seems a susceptible 3 
period in terms of safety events.  4 
To understand what these real-life bleeding data can imply in our meta-analytic population, should 5 
this population be anticoagulated for 30 days after the cardioversion, some assumptions need to be 6 
taken. First, due to the correlation between CHA2DS2-VASc and HAS-BLED 15, we can assume 7 
that HAS-BLED would range between 0-1 in the examined population. Second, based on the 8 
estimation of bleeding risk in the original validation cohort of HAS-BLED score across the 9 
different categories 16, bleeding risk of patients with HAS-BLED 0-1 is reduced by 43% compared 10 
to the risk of patients with HAS-BLED 2. Given these postulations, in case of short-term OAT, the 11 
expected 30-day incidence of major bleedings in the present population, assuming low HAS-BLED 12 
score (0-1), could be supposed 0.46%.  13 
This means that, in order to reduce a 30-day 0.1% risk of a thromboembolic complication, initiation 14 
of a short-term OAT might expose the patient to a 0.46% risk of experiencing a major bleeding 15 
during the 4 weeks of therapy, with the risk of a potentially fatal intracranial bleeding projected at 16 
0.08% (17% of major bleedings were intracranial bleedings in the study from Danish national 17 
registry 14) (Figure 3).  18 
Although to be confirmed in large-scale studies, in our opinion, these data, together with those of  19 
randomized and real-world data concerning the bleeding risk conferred by OAT, suggest that a 20 
strategy of short-term anticoagulation after acute CV of early-onset AFib, in this specific setting of 21 
patients, should be discouraged. The therapeutic choice following CV should be between no-OAT 22 
strategy and initiation of a long-term OAT. A no-OAT strategy appears a reasonable choice, at least 23 
in patients with CHA2DS2-VASc 0, possibly coupled with a timely cardioversion. In fact, based on 24 
the Finnish Cardioversion registry (FinCV) data, if the cardioversion is performed by 12 hours after 25 
symptoms onset a nearly four-fold reduction in thromboembolic risk at 30-days is reported in non-26 
 8 
anticoagulated patients 17.  1 
 2 
Limitations 3 
First, lack of complete sex subgroup data in the included studies precluded the possibility to 4 
specifically analyze thromboembolic incidence in females without (CHA2DS2-VASc 1) and with a 5 
single stroke risk factor other than gender (CHA2DS2-VASc 2), 18. Second, additional stroke risk 6 
factors accounted for in the CHA2DS2-VASc score (other than gender) may have different impact in 7 
terms of increased thromboembolic risk 19. The impossibility of performing meta-regression 8 
analyses, due to low number of studies included (< 5) and the lack of complete baseline 9 
characteristics of the subgroup of CHA2DS2-VASc 0-1 patients in most of the studies, unfortunately 10 
limits the possibility to account for single variables. Finally, the fact that some patients in the 11 
included studies received more than one cardioversion should be regarded as a possible confounder. 12 
 9 
Conclusion 1 
Thromboembolic complications following acute CV of early-onset AFib (< 48 hours) in patients 2 
not assuming OAT and having low-moderate thromboembolic risk (CHA2DS2-VASc 0-1) are rare 3 
(30-day incidence: 0.10%, 95% CI 0.00-0.30%). Given this, and the knowledge that the OAT-4 
associated major bleeding risk is higher in the first 30 days after treatment initiation, short-term 5 
anticoagulation (4 weeks) following acute CV of early-onset AFib should be discouraged. At index 6 
presentation the focus should be on a careful patient assessment in order to establish whether long-7 






Figure Legends 1 
Figure 1. Study flow diagram.  2 
 3 
Figure 2. Forest plot of 30-day incidence of thromboembolic complication following 4 
cardioversion.  5 
 6 
Figure 3. 30-day incidence of thromboembolic events and expected major bleedings 7 
following cardioversion of early onset atrial fibrillation in patients with low-moderate 8 
thromboembolic risk (a), with distribution of major bleeding subtypes (b). *Expected 9 
major bleeding incidence and major bleeding subtype distribution are based on data by 10 




































































490 66 (66) 61 nr Electrical 100% LMWH 81% 
LMWH, Low Molecular Weight Heparin; nr, not reported 5 
*Estimation based on the cardioversion-to-patient ratio in the entire cohort (1.17 6 
cardioversions per patient)  7 
** This study only included patients at low cardio-embolic risk 8 
***Referred to CHA2DS2-VASc 0-1 patients, irrespective of anticoagulation status  9 
****Comprised cardioversions performed either without anticoagulation or on warfarin with 10 
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